Loading…
Loading…
INSP does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for INSP and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for INSP and 80,000+ other tickers.
See exactly how INSP's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for INSP and 80,000+ other tickers.
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously…
Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.
On October 09, 2026, Inspire Medical Systems Inc (INSP) shares rose 3.3% to $68.89, navigating a volatile 52-week range of $38.91 to $147.03. The stock's recent
Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRCPR NewswireJOHANNESBURG, Oct. 7, 2026Roche Diagnostics has provided two molecular
MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, November 2. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
INSP gains new Category I CPT codes for Inspire V procedures, creating a dedicated coding framework effective Jan. 1, 2028.